Combination of <i>in vivo</i> phage therapy data with <i>in silico</i> model highlights key parameters for treatment efficacy

Raphaëlle Delattre(Centre National de la Recherche Scientifique), Laurent Debarbieux(House of Representatives), Jean-Damien Ricard(Inserm), Baptiste Gaborieau(Centre National de la Recherche Scientifique), Rokhaya Kane(Centre National de la Recherche Scientifique), Jérémie Guedj(Inserm), Nicolas Dufour(Centre Hospitalier René-Dubos), Feyrouz Haddad(Centre National de la Recherche Scientifique), Thu-Thuy Nguyen(Inserm), Jérémy Seurat(Inserm)
bioRxiv (Cold Spring Harbor Laboratory)
March 4, 2021
10.1101/2021.03.04.433924
Cited by 0

Related Papers

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19
|JAMA|2020|518
The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline
|Intensive Care Medicine|2020|413
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
|Science|2020|382
Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure
|JAMA|2019|353
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344